12/3
10:33 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
12/3
10:33 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
12/3
08:44 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $516.00 price target on the stock.
Medium
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $516.00 price target on the stock.
12/3
08:44 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $516.00 price target on the stock.
Medium
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $516.00 price target on the stock.
12/3
05:06 am
vrtx
Vertex upgraded to Overweight from Equal Weight at Morgan Stanley
Medium
Report
Vertex upgraded to Overweight from Equal Weight at Morgan Stanley
12/3
05:06 am
vrtx
Vertex upgraded to Overweight from Equal Weight at Morgan Stanley
Medium
Report
Vertex upgraded to Overweight from Equal Weight at Morgan Stanley
11/14
07:54 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
11/14
07:54 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
11/13
09:53 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $495.00 price target on the stock.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $495.00 price target on the stock.
11/13
09:53 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $495.00 price target on the stock.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $495.00 price target on the stock.
11/12
04:19 pm
vrtx
Vertex Pharmaceuticals initiated with an Outperform at Scotiabank
Low
Report
Vertex Pharmaceuticals initiated with an Outperform at Scotiabank
11/12
04:19 pm
vrtx
Vertex Pharmaceuticals initiated with an Outperform at Scotiabank
Low
Report
Vertex Pharmaceuticals initiated with an Outperform at Scotiabank
11/7
01:22 pm
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
11/4
11:44 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
11/4
11:44 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
11/4
09:19 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
11/4
09:19 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
11/4
07:39 am
vrtx
Rating for VRTX
Medium
Report
Rating for VRTX
10/10
01:30 pm
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
10/10
01:30 pm
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
10/8
01:46 pm
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
10/2
01:42 pm
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
10/2
01:42 pm
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
9/25
08:06 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $456.00 price target on the stock, down previously from $458.00.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $456.00 price target on the stock, down previously from $458.00.
9/25
06:50 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX